Floatz logo

Anbalcabtagene Autoleucel

Primary CNS Lymphoma (PCNSL)

Hyungwoo ChoCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

73 Active assets in the Primary CNS Lymphoma (PCNSL) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BBB
(+)-VINCRISTINE
Ono Pharmaceutical Co., Ltd.
Phase 4BBB
METHOTREXATE
Assistance Publique Hopitaux De Marseille
Phase 4BB
Idarubicine
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BB
Orelabrutinib
The First Affiliated Hospital with Nanjing Medical University
Phase 3BB

View all 50 →

Same molecule, other indications

Anbalcabtagene Autoleucel is also rated in:

diffuse large B-cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →